ProKidney Ord Shs Class A shares are trading sharply higher Wednesday morning, following a marked surge on Tuesday driven by positive clinical trial data for its chronic kidney disease (CKD) treatment.

The company’s shares are gaining again Wednesday as investors continue to cheer statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial for rilparencel.

What To Know: Early Wednesday, ProKidney’s stock hit a session volume of 165 million, a massive leap from its average of 6.65 million. The momentum was sparked by the announcement that its autologous cellular therapy, rilparencel, demonstrated a significant ability to preserve kidney function in patients with CKD and diabetes.

The pivotal data from Group 1 of the trial showed a 78% improvement in the annual decline of the estimated glomerular filtration rate (eGFR), a key measure of kidney function.

This result was both statistically significant (p